The Biology and Symptoms of Coffin-Lowry Syndrome

Understanding the symptoms and biology of Coffin-Lowry Syndrome (CLS) requires looking closely at the intersection of genetics, cognitive development, and physical features. Return to the Home Page for an overview.

The Role of the RPS6KA3 Gene

The biological “blueprint” for CLS is found in the RPS6KA3 gene ^[1]. This gene provides the instructions for making a protein called RSK2 ^[2].

RSK2 acts like a switch in a complex communication network called the MAPK signaling pathway ^[3]. This pathway is vital for:

• Brain Function: RSK2 helps regulate synaptic plasticity, which is the brain’s ability to change and adapt. This is essential for learning and memory ^[4][5].
• Bone Health: It plays a role in maintaining bone density and the health of the teeth and jaw ^[6].
• Cell Growth: It tells cells when to grow and how to respond to their environment ^[2].

In CLS, the mutated RPS6KA3 gene leads to a deficiency of the RSK2 protein ^[2]. Without enough of this protein, the “switches” in the brain and body don’t function correctly ^[4].

X-Linked Inheritance and the “Mosaic” Effect

CLS follows an X-linked dominant inheritance pattern ^[7]. This creates a significant difference in how the syndrome affects males and females:

• In Males: Because males have only one X chromosome, a mutation in that single gene means they have very little to no functional RSK2 protein ^[8]. Males are typically more severely affected, experiencing significant intellectual disability and more pronounced physical features ^[8][7].
• In Females: Females have two X chromosomes. Through a natural process called X-inactivation, one X chromosome is randomly “turned off” in every cell ^[9]. This creates a cellular mosaicism—some cells use the healthy X chromosome, while others use the mutated one ^[10]. Therefore, females show a massive range of symptoms. Some may have no symptoms, while others may have challenges as severe as those seen in males ^[9][10].

Cognitive and Developmental Profile

While much medical literature focuses on physical traits, the most profound day-to-day impact for families is the cognitive and developmental reality of the syndrome. It is crucial to set honest but supportive expectations:

• Intellectual Disability: Most males, and some females, with CLS experience moderate to severe intellectual disability. This means that cognitive milestones will be delayed, and specialized, lifelong educational support will be required ^[11][8].
• Communication Challenges: Speech is often significantly delayed. Many children will require augmentative and alternative communication (AAC) devices or sign language to help them express their needs ^[11]. The lack of speech can be a source of frustration, but working closely with speech-language pathologists early on can create pathways for communication.
• Motor Delays: Due to low muscle tone (hypotonia) and joint hypermobility, sitting, crawling, and walking are usually achieved later than typical peers ^[12][8].

Physical Features for Diagnosis

A diagnosis is often first suspected based on a “constellation” of physical signs that doctors call dysmorphism ^[13].

Facial Characteristics

These features often become more distinct as a child enters later childhood:

• Prominent Forehead: A broad or forward-projecting forehead ^[13].
• Hypertelorism: Widely spaced eyes ^[13].
• Thick Lips and Large Mouth: The lips may appear full, and the mouth is often wide ^[7].
• Down-slanted Eyes: The outer corners of the eyes may point downward ^[13].

Distinctive Hand Findings

The hands in CLS are very characteristic:

• “Puffy” Appearance: The hands and fingers often appear soft, fleshy, and swollen ^[13][12].
• Tapered Fingers: The fingers are often broad at the base and become narrower toward the tips ^[13].
• Hyperextensibility: The finger joints may be exceptionally flexible or “double-jointed” ^[12].

Diagnosis is established through identification of these features paired with developmental delays, and then officially confirmed by molecular genetic testing of the RPS6KA3 gene ^[8][14].